Crossmark

Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study

Crossref DOI link: https://doi.org/10.1016/j.remnie.2021.05.005

Published Print: 2022-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Zarehparvar Moghadam, Soroush

Askari, Emran

Divband, Ghasemali

Shakeri, Sara

Aryana, Kamran
Funding

Funding for this research was provided by:

Mashhad University of Medical Sciences (960570)
License Information

Text and Data Mining valid from 2022-07-01
More Information

This article is maintained by: Elsevier

Article Title: Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study

Journal Title: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.remnie.2021.05.005

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.remn.2021.03.015

Content Type: article

Copyright: © 2021 Sociedad Española de Medicina Nuclear e Imagen Molecular. Published by Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below